Sirius Genomics

Vancouver, Canada-based Sirius Genomics is using arrays to develop a test to identify individuals who respond to the hormone vasopressin and similar compounds for the treatment of septic shock.

The two firms will partner to develop diagnostics to identify individuals who respond well to Vasopressin and other compounds for the treatment of septic shock and related conditions.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pairings

Premium

Kamran Alam, Stan Lapidus

Pairings

Premium

Chris Wagner, Brad Popovich, Jorge Garces, Greg Hamilton, Nick Williams, Darren Hall

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Sirius will work with a system of 37 hospitals to test biomarkers for severe sepsis drug response.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.